Trial Profile
REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Cancer metastases; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms REACHIN
- 30 Jul 2020 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
- 25 May 2020 Results evaluating efficacy of Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors, published in the Annals of Oncology
- 31 May 2019 Results of exploratory analysis published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).